Richard Goldberg, MD, discusses results from the phase III CALGB/SWOG 80405 trial at the 2014 ASCO Annual Meeting.
Richard Goldberg, MD, Physician-in-Chief at Ohio State’s Comprehensive Cancer Center James Cancer Hospital and Solove Research Institute, discusses results from the phase III CALGB/SWOG 80405 trial at the 2014 ASCO Annual Meeting. The CALGB/SWOG 80405 trial looked at irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab or cetuximab for patients with KRAS wild-type untreated metastatic adenocarcinoma of the colon or rectum (mCRC).
<<<
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More